文献速递先天性心脏病外科

小儿先天性心脏病手术中灌注模式的随机临床试验

A Randomized Clinical Trial of Perfusion Modalities in Pediatric Congenital Heart Surgery Patients.
PubMed 文献 · Ann Thorac Surg · 2022-03-12

这项随机临床试验纳入159例先天性心脏病手术患者,比较搏动性灌注(n=83)与非搏动性灌注(n=76)对脑血流动力学、PELOD-2评分及临床结局的影响。结果显示搏动性组大脑中动脉和动脉管路的搏动指数维持更好,但两组临床结局和PELOD-2评分无统计学差异,搏动性灌注安全但非「灵丹妙药」。

要点

  • 搏动性灌注组大脑中动脉及动脉管路搏动指数在主动脉阻断期间维持更好。
  • 两组临床结局(插管时间、ICU住院时间、总住院时间、死亡率)无差异。
  • PELOD-2评分24至72小时逐步改善,但两组间无统计学差异。

核心结论

  • 搏动性灌注组的搏动指数呈现更符合生理的模式,但未改善临床结局或PELOD-2评分,提示搏动性灌注是安全方法但并非先天性心脏手术的「灵丹妙药」。

研究设计与样本

  • 随机临床试验,纳入159例连续先天性心脏病手术患者,搏动性灌注组83例,非搏动性灌注组76例。
  • 采用经颅多普勒超声评估脑血流动力学,在24、48、72小时用PELOD-2评分量化多器官损伤。

主要发现

  • 主动脉阻断期间大脑中动脉和动脉管路的搏动指数在搏动性组持续维持更好。
  • 两组人口学特征和体外循环特征相似。
  • 两组STAT死亡分类相似,但死亡分类1至3的患者多于分类4和5。
  • 两组临床结局(插管时间、ICU住院时间、住院时间、死亡率)无差异。
  • PELOD-2评分从24小时至72小时逐步改善,但两组间结果无统计学差异。

关键数值与推荐

  • 搏动性灌注未增加血浆游离血红蛋白水平或微栓子释放。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this randomized clinical trial was to investigate the effects of perfusion modalities on cerebral hemodynamics, vital organ injury, quantified by the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) Score, and clinical outcomes in risk-stratified congenital cardiac surgery patients. METHODS: This randomized clinical trial included 159 consecutive congenital cardiac surgery patients in whom pulsatile (n = 83) or nonpulsatile (n = 76) perfusion was used. Cerebral hemodynamics were assessed using transcranial Doppler ultrasound. Multiple organ injury was quantified using the PELOD-2 score at 24, 48, and 72 hours. Clinical outcomes, including intubation time, intensive care unit length of stay (LOS), hospital LOS, and mortality, were also evaluated. RESULTS: The Pulsatility Index at the middle cerebral artery and in the arterial line during aortic cross-clamping was consistently better maintained in the pulsatile group. Demographics and cardiopulmonary bypass characteristics were similar between the 2 groups. While risk stratification with The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) Mortality Categories was similar between the groups, Mortality Categories 1 to 3 demonstrated more patients than Mortality Categories 4 and 5. There were no differences in clinical outcomes between the groups. The PELOD-2 scores showed a progressive improvement from 24 hours to 72 hours, but the results were not statistically different between the groups. CONCLUSIONS: The Pulsatillity Index for the pulsatile group demonstrated a more physiologic pattern compared with the nonpulsatile group. While pulsatile perfusion did not increase plasma-free hemoglobin levels or microemboli delivery, it also did not demonstrate any improvements in clinical outcomes or PELOD-2 scores, suggesting that while pulsatile perfusion is a safe method, it not a "magic bullet" for congenital cardiac operations.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Ündar A, Patel K, Holcomb RM, et al. A Randomized Clinical Trial of Perfusion Modalities in Pediatric Congenital Heart Surgery Patients. Ann Thorac Surg. 2022. PMID: 35292258. doi:10.1016/j.athoracsur.2022.02.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。